Following its listing on the LSE Main Market in October 2025, Cindrigo has now moved into an executi...
Redeye provides its first take on Oncopeptides' Q1 report 2026.
Redeye retains its positive view of Transtema despite a softer-than-expected Q1.
The takeaway from Eckert & Ziegler’s Q1 results is positive: Medical delivered strong underlying gro...
Redeye returns with an update following SciBase Holding’s Q1 report, which largely met our expectati...
* Volumes stronger than expected * Gross margin continues to be steady at ~44% * DOCS now penetrated...
Redeye provides an update following CSG’s Q4 2025/2026 report, which showed sales above our estimate...
Redeye updates on Better Collective ahead of Q1-results (due 20 May after market close) where we exp...
* EC IFPM p.s. +7% q-o-q * Renewed mandate for 10% SBBs * 2026e P/CEPS 10x vs.
Redeye provides an update following CLS’s Q1 2026 report.
Fiskars hosted its CMD event yesterday. The company announced new financial targets for 2026-30 whic...
* Orviglance data accepted for presentation at high-quality congress * Cash runway into 2027 * Fair ...
Sales took a backwards step in Q1, with all regions posting a muted performance.
Today, new data from BI-1808 in cutaneous T-cell lymphoma were presented.
Hyresintäkterna steg 5,5% till 129,0 mkr drivet av indexering och högre uthyrningsgrad (95,5%).
Hyresintäkterna ökade 15% till 208 mkr drivet av förvärv, indexering och investeringar.
* Svedbergs Group acquires Czech Group UBC s.r.o. * Acquires 80% initially, remaining 20% planned in...
Envar rapporterade för Q1’26 en nettoomsättning om 25,8 MSEK (22,7), motsvarande en tillväxt om 13,6...
Endomines Q1 results were operatively well in line with our expectations, with revenue at EUR 18.
CTEK delivered a relatively strong Q1 report despite continued weak end markets, with Consumer once ...